It does make you wonder Next. I sometimes wonder why with all the great science Don hasn't made a modest private placement with a big pharma where Apabetalone would fit into their pipeline in the (near) future. Similar to the way Pfizer invested in Trillium, which was done at a premium to market.

To me obvious targets would be Boehringer Ingleheim or Lilly, or both since they are partners in Jardiance. Neither one is doing much with covid so I'm sure some participation in that segment would be welcome and since they co-own Jardiance there are obvious positives in that respect.